As of November 14, 2026, Avadel Pharmaceuticals Plc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 12, 2026 (Form 8-K, February 12, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Avadel Pharmaceuticals Plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Avadel Pharmaceuticals Plc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-12. Every row below is cited to the filing it comes from, and this page adds each new change as Avadel Pharmaceuticals Plc files it.
Also on the record for Avadel Pharmaceuticals Plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 1.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Two Seas Capital LP | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by BRANDES INVESTMENT PARTNERS, LP | 0.2% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G/A, by Jeffrey L. Gendell | 4.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 7.7% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 11.5% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G/A, by Two Seas Capital LP | 6.4% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G, by The Vanguard Group | 5.74% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G, by The Vanguard Group | 5.74% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Avadel Pharmaceuticals Plc now and the warning signs.
Free to see. No signup.
Keep reading
More on Avadel Pharmaceuticals Plc and the records around it.
Avadel Pharmaceuticals Plc elsewhere on the record
- 5%+ stake filings Feb 2026
Companies that share a holder
- Tontine Asset Associates, LLC also filed stake reports on 7 other companies: Nine Energy Service, Inc. (Aug 2026), IF Bancorp, Inc. (May 2026), Drilling Tools International Corp (Feb 2026)
- Two Seas Capital LP also filed stake reports on 14 other companies: NEKTAR THERAPEUTICS (Sep 2026), Calumet, Inc. (Aug 2026), Quantum Corporation (Aug 2026)
- BRANDES INVESTMENT PARTNERS, LP also filed stake reports on 26 other companies: Globant S.A. (Oct 2026), American Outdoor Brands, Inc. (Aug 2026), HURCO COMPANIES INC (Aug 2026)
Watch Avadel Pharmaceuticals Plc
Get an email when Avadel Pharmaceuticals Plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Avadel Pharmaceuticals Plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Avadel Pharmaceuticals Plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avadel Pharmaceuticals Plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-12 | Reported | not named in the filing | 8-K, 2026-02-12 |
New leaders reset buying decisions — get the Full Report on Avadel Pharmaceuticals Plc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Avadel Pharmaceuticals Plc, with the record behind each one.
Find candidates like senior executive at Avadel Pharmaceuticals PlcEvery change, in the filing's words
Reported
In connection with the Acquisition and as of the Effective Time, Gregory J. Divis (Chief Executive Officer), Thomas S. McHugh (Chief Financial Officer), Susan Rodriguez (Chief Operating Officer) and Jerad G. Seurer (General Counsel and Corporate Secretary) ceased to serve in their capacities as executive officers of Avadel.
- Additionally, as of the Effective Time, each of Geoffrey M. Glass, Gregory J. Divis, Dr. Eric J. Ende, Dr. Mark A. McCamish, Linda S. Palczuk, Peter J. Thornton and Dr. Naseem S. Amin ceased serving as a member of the board of directors of Avadel and each committee thereof on which such director served.
Tools for this story
Each opens in a new tab, filled in for Avadel Pharmaceuticals Plc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
